Summary & Overview
CPT 17312: Mohs Micrographic Surgery for Skin Cancer in Sensitive Areas
CPT code 17312 represents the Mohs micrographic technique, a highly specialized surgical procedure for the treatment of skin cancers in anatomically sensitive or complex areas such as the head, neck, hands, feet, genitalia, or sites involving critical structures like muscle, cartilage, bone, tendon, major nerves, or vessels. This code encompasses the complete process of tumor removal, tissue mapping, color coding, and microscopic examination by the surgeon, along with histopathologic preparation using routine stains. Mohs surgery is recognized for its precision and tissue-sparing approach, making it a preferred method for managing skin cancers in challenging locations.
Nationally, this procedure is covered by major payers including Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare. The publication provides a comprehensive overview of payer coverage, clinical benchmarks, and recent policy updates relevant to Mohs micrographic surgery. Readers will gain insight into the clinical context of the procedure, typical sites of service, and the importance of accurate coding for reimbursement and compliance. The analysis also highlights related codes and modifiers, offering clarity on billing practices and payer requirements for this complex dermatologic service.
CPT Code Overview
CPT code 17312 describes the Mohs micrographic technique, a specialized dermatologic surgical procedure used for the treatment of skin cancers. This procedure involves the removal of all visible tumor tissue, surgical excision of specimens, mapping and color coding of the excised tissue, and microscopic examination by the surgeon. Histopathologic preparation, including routine stains such as hematoxylin and eosin or toluidine blue, is also included. The code applies to procedures performed on the head, neck, hands, feet, genitalia, or any location where surgery directly involves muscle, cartilage, bone, tendon, major nerves, or vessels. Mohs micrographic surgery is most commonly performed in an outpatient setting, such as a physician's office.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an adult presenting to a dermatology clinic with a biopsy-confirmed diagnosis of basal cell carcinoma or squamous cell carcinoma located on the head, neck, hands, feet, genitalia, or an area where surgery directly involves muscle, cartilage, bone, tendon, major nerves, or vessels. The patient is scheduled for Mohs micrographic surgery, which is performed in an outpatient office setting. The procedure includes excision of the tumor, mapping and color coding of tissue specimens, and microscopic examination by the surgeon to ensure complete removal of cancerous cells. Multiple stages may be required depending on the extent of the tumor. The clinical workflow includes preoperative assessment, surgical excision, intraoperative histopathologic evaluation, and wound reconstruction as needed.
Coding Specifications
- Modifier
59: Used to indicate a distinct procedural service. This modifier is applied when Mohs micrographic surgery is performed on a separate lesion on the same day, as per CMS billing guidance.
| Modifier Code | Description |
|---|---|
59 | Distinct procedural service – when Mohs on separate lesion same day requires -59 modifier per CMS billing guidance |
- Provider Taxonomies:
| Taxonomy Code | Specialty |
|---|---|
207ND0101X | Dermatology Physician |
207NS0135X | MOHS-Micrographic Surgery Physician |
207N00000X | Dermatopathology Physician |
These taxonomies represent providers specializing in dermatology, Mohs micrographic surgery, and dermatopathology, all of whom may be involved in the procedure and interpretation of tissue specimens.
Related Diagnoses
-
C44.01: Basal cell carcinoma of skin of lip- Relevant for Mohs surgery when the carcinoma is located on the lip, a high-risk area requiring precise excision.
-
C44.111: Basal cell carcinoma of skin of right eyelid- Indicates basal cell carcinoma on the right eyelid, an anatomically sensitive site often managed with Mohs surgery.
-
C44.21: Squamous cell carcinoma of skin of right ear and external auricular canal- Represents squamous cell carcinoma in the right ear region, where Mohs surgery is indicated due to complex anatomy.
-
C44.310: Basal cell carcinoma of skin of unspecified parts of face- Used when basal cell carcinoma is present on the face but the exact location is unspecified; Mohs surgery is preferred for facial lesions.
-
D04.5: Carcinoma in situ of skin of trunk- Refers to carcinoma in situ on the trunk, which may be treated with Mohs surgery depending on clinical factors.
Related CPT Codes
-
17311: First stage Mohs micrographic surgery procedure (anatomic site-specific). Used for the initial stage of Mohs surgery, typically on areas such as the head, neck, hands, feet, or genitalia. -
17314: Additional stages with first stage code17313(Mohs on trunk, arms, legs). Used when further excision stages are required after the initial stage, specifically for trunk, arms, or legs. -
17315: Each block after the first 5 blocks for any single stage. Used to report additional tissue blocks beyond the first five in any single stage of Mohs surgery.
These codes are commonly used together in a clinical workflow when multiple stages or tissue blocks are required to ensure complete tumor removal. 17311 and 17312 are site-specific first stage codes, while 17314 and 17315 are used for additional stages or blocks as needed.
National Reimbursement Benchmarks
For CPT code 17312, the national mean rate for Medicare is $417.84, closely aligned with Aetna at $417.96 and Blue Cross Blue Shield at $408.75. The BUCA (average commercial) mean rate stands at $438.60, slightly higher than Medicare. UnitedHealth Group and Cigna report notably higher mean rates at $555.73 and $502.54, respectively.
Rate dispersion varies significantly across payers. Medicare exhibits the tightest range between the 75th and 25th percentiles ($46.00), indicating more consistent reimbursement. In contrast, UnitedHealth Group shows the widest spread ($305.67), reflecting greater variability in commercial rates. Cigna also demonstrates substantial dispersion ($277.67), while Aetna and Blue Cross Blue Shield are more moderate. The table and chart below present the full breakdown of national benchmarks for each payer.
State Benchmarks
State: AK1 / 50
Alaska Benchmarks
Alaska exhibits a wide spread in reimbursement rates for CPT code 17312, with the highest payer (Aetna) offering a mean rate of $1,270.66 and the lowest (Medicare) at $403.53. The rate spread, measured by the difference between the 75th and 25th percentiles, is most pronounced for Blue Cross Blue Shield ($414.90) and BUCA ($464.39), indicating significant variability among commercial payers. In contrast, Aetna's percentiles are uniform, suggesting a consistent rate across providers.
Compared to national averages, all payers in Alaska reimburse at substantially higher rates for CPT code 17312. For example, Aetna's mean rate in Alaska is more than triple its national mean, and UnitedHealth Group's mean rate is nearly double the national benchmark. The table and chart below present the full breakdown of payer-specific rates in Alaska.
Key Insights for Alaska
- Aetna is the highest paying payer in Alaska for CPT 17312, with a mean rate of $1,270.66.
- Medicare is the lowest paying payer, with a mean rate of $403.53, significantly below the commercial payers.
- All Alaska payer mean rates are substantially higher than their respective national averages, with Aetna's mean rate more than triple the national benchmark.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.